Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEST: Aspirin for Pre-eclampsia Prevention
NCT03674606Phase 4Completed
- Sponsor
- University College Dublin
- Start
- Feb 2014
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in preeclampsia and fetal growth restriction (FGR) (3 arms), sponsored by University College Dublin. Primary endpoints: Proportion of eligible women that agree to participate up to 40 weeks, Adherence to aspirin if prescribed at 36 weeks and 2 more. Started Feb 2014; status: completed.
02
Drugs
aspirin
03
Conditions
preeclampsiafetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT03674606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674606.